In:
The Journal of Clinical Pharmacology, Wiley, Vol. 58, No. 7 ( 2018-07), p. 905-912
Abstract:
Udenafil is a phosphodiesterase‐5 inhibitor used to treat erectile dysfunction. Although udenafil is not predominantly eliminated by the kidney, renal impairment can alter its secretion/transport pathways. Drug pharmacokinetics and safety must therefore be assessed in subjects with a renal impairment. We investigated the effects of impaired renal function on the pharmacokinetics and safety of a single 100‐mg oral dose of udenafil in a single‐dose, open‐label, parallel‐group study of 31 subjects. Cockcroft‐Gault creatinine clearance was used to stratify these subjects into healthy controls ( 〉 80 mL·min −1 ) and individuals with mild (50 to ≤80 mL·min −1 ), moderate (30 to ≤50 mL·min −1 ), and severe ( 〈 30 mL·min −1 ) renal impairment. Pharmacokinetic measurements and safety assessments indicated that the geometric mean of the area under the concentration‐time curve to the last measurement in mildly, moderately, and severely renally impaired subjects was 1.30‐ (90% CI 1.05‐1.60), 1.62‐ (90% CI 1.28‐2.06), and 1.60‐ (90% CI 1.28‐2.01) fold higher, respectively, than the healthy controls. The geometric mean of the maximum observed concentration was 1.41‐ (90% CI 1.05‐1.88), 2.02‐ (90% CI 1.47‐2.79), and 1.65‐ (90% CI: 1.21‐2.24) fold higher, respectively. Significant correlations were observed among the creatinine clearance, oral clearance, and maximum concentration of udenafil ( P 〈 .01). All adverse events were mild, and no subject discontinued the study. Udenafil administration was well tolerated in all groups. In view of the clinical relevance of drug exposure, our findings indicate that a dose adjustment of udenafil is warranted in subjects with moderate or severe renal impairment.
Type of Medium:
Online Resource
ISSN:
0091-2700
,
1552-4604
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2010253-7
SSG:
15,3
Permalink
